Format

Send to

Choose Destination
Biomed Res Int. 2015;2015:207312. doi: 10.1155/2015/207312. Epub 2015 Jan 11.

GABAB receptor antagonist CGP46381 inhibits form-deprivation myopia development in guinea pigs.

Author information

1
Clinical College of Ophthalmology, Tianjin Medical University, Tianjin Eye Hospital, 4 Gansu Road, Heping District, Tianjin 300020, China ; Department of Ophthalmology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
2
The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
3
School of Optometry and Vision Science, Faculty of Health, and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
4
Tianjin Nankai High School, 22 Nankaisima Road, Nankai District, Tianjin 300100, China.
5
Department of Ophthalmology, The Second People's Hospital of Jinan, Jinan, Shandong 250001, China.
6
Department of Ophthalmology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, China.
7
Clinical College of Ophthalmology, Tianjin Medical University, Tianjin Eye Hospital, 4 Gansu Road, Heping District, Tianjin 300020, China.

Abstract

The aim was to investigate the effects of the GABAB receptor antagonist, CGP46381, on form-deprivation myopia (FDM) in guinea pigs. Twenty-four guinea pigs had monocular visual deprivation induced using a diffuser for 11 days (day 14 to 25). The deprived eyes were treated with daily subconjunctival injections (100 μl) of either 2% CGP46381, 0.2% CGP46381, or saline or received no injection. The fellow eyes were left untreated. Another six animals received no treatment. At the start and end of the treatment period, ocular refractions were measured using retinoscopy and vitreous chamber depth (VCD) and axial length (AL) using A-scan ultrasound. All of the deprived eyes developed relative myopia (treated versus untreated eyes, P < 0.05). The amount of myopia was significantly affected by the drug treatment (one-way ANOVA, P < 0.0001). The highest dose tested, 2% CGP46381, significantly inhibited myopia development compared to saline (2% CGP46381: -1.08 ± 0.40 D, saline: -4.33 ± 0.67 D, P < 0.01). The majority of these effects were due to less AL (2% CGP46381: 0.03 ± 0.01 mm, saline: 0.13 ± 0.02 mm, P < 0.01) and VCD (2% CGP46381: 0.02 ± 0.01 mm, saline: 0.08 ± 0.01 mm, P < 0.01) elongation. The lower dose tested, 0.2% CGP46381, did not significantly inhibit FDM (P > 0.05). Subconjunctival injections of CGP46381 inhibit FDM development in guinea pigs in a dose-dependent manner.

PMID:
25649745
PMCID:
PMC4306252
DOI:
10.1155/2015/207312
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center